Financial Support for Patients on ONCASPAR®
750 U/ml powder for solution for injection/infusion
ServierONE works to connect you to the right support programs and services that may help you access ONCASPAR 750 U/ml powder for solution for injection/infusion.
We offer:
- Support with insurance coverage and reimbursement
- Financial assistance to help eligible patients pay for ONCASPAR 750 U/ml powder for solution for injection/infusion
- Access to a one-on-one Patient Experience Manager
Click logo for Important Safety Information.
Eligible Patients Could Receive Access to Medication with the ONCASPAR 750 U/ml powder for solution for injection/infusion Patient Assistance Program
How to enroll in the ONCASPAR 750 U/ml powder for solution for injection/infusion Patient Assistance Program (PAP)
Step 1
Step 2
Step 3
Step 4
If you have questions or need assistance, contact ServierONE Patient Support Program.
Please call 1-800-813-5905, Monday through Friday,
8 AM to 8 PM ET.
Or email us at
USPatientServices@servier.com.
If you have questions, please call 1-800-813-5905 , Monday through Friday, 8 AM to 8 PM ET.
ONCASPAR® IMPORTANT SAFETY INFORMATION AND APPROVED USE
ONCASPAR should not be given to patients who have had:
- Serious allergic reactions to ONCASPAR (pegaspargase) or any of its ingredients.
- Serious blood clots, serious inflammation of the pancreas (abdominal pain), or serious bleeding during previous L-asparaginase treatment.
- Serious impairment of liver function.
ONCASPAR may cause serious side effects including:
- Allergic reactions (Symptoms: hives and itching, a swollen tongue or throat, trouble breathing, dizziness, fainting).
- Inflammation of the pancreas (Symptoms: severe stomach pain, nausea, vomiting, fever, chills, diarrhea).
- Blood clots (Symptoms: severe headache, arm or leg swelling, shortness of breath, chest pain).
- Increased/excess sugar in the blood (Symptoms: Excessive thirst, increased amount of urine or urinary frequency).
- Unusual bleeding or bruising.
- Liver problems, including severe, life-threatening, or fatal veno-occlusive liver disease (VOD), and abnormalities in liver tests may develop during ONCASPAR treatment. Contact your doctor immediately if you experience jaundice, rapid weight gain, abdominal swelling, or right upper abdominal pain or tenderness.
Call or see your doctor right away if you develop any of these serious side effects or if symptoms get worse.
Before receiving ONCASPAR, tell your doctor about all your medical conditions, including if you:
- are pregnant or plan to become pregnant. ONCASPAR can harm your unborn baby. You should not become pregnant during treatment with ONCASPAR. Tell your doctor right away if you become pregnant or think you may be pregnant during treatment with ONCASPAR.
- Females who are able to become pregnant: You should use effective non-hormonal birth control (contraception) during treatment with ONCASPAR and for at least 3 months after the last dose.
- are breastfeeding or plan to breastfeed. It is not known if ONCASPAR passes into your breast milk. Do not breastfeed during treatment with ONCASPAR and for 1 month after your last dose.
How will I receive ONCASPAR?
- ONCASPAR will be given to you as an injection by your doctor as part of your chemotherapy treatment plan. It is important that you receive all of your treatment doses according to your doctor’s instructions.
- During treatment, you will be monitored, and if you experience side effects, your doctor may have to change your treatment.
The most common side effects of ONCASPAR include: low albumin blood level (hypoalbuminemia), elevated liver enzymes, fever with low white blood cell count, abnormal elevation of triglyceride levels in the blood (hypertriglyceridemia), a high level of blood sugar (hyperglycemia), increased bilirubin level, inflammation of the pancreas, abnormal clotting studies, embolic and thrombotic events, allergic reactions, sepsis, and infections.
This is not a complete list of side effects that may occur. Call your doctor for medical advice about any side effects especially if they do not go away.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Servier Pharmaceuticals LLC at 1-800-807-6124.
For additional information, please refer to the ONCASPAR Full Prescribing Information and discuss any questions with your doctor.
ONCASPAR is a registered trademark of Servier IP UK Ltd., a wholly-owned, indirect subsidiary of Les Laboratoires Servier. Servier and the Servier logo are trademarks of Les Laboratoires Servier.
INDICATIONS AND USAGE
Approved use for ONCASPAR
ONCASPAR is a prescription medicine that is given as part of a chemotherapy treatment plan
to treat children and adult patients who have acute lymphoblastic leukemia (ALL), especially
for those patients who are allergic to native forms of L-asparaginase. ALL is a type of cancer
in which the bone marrow makes too many abnormal white blood cells that may crowd out normal
red blood cells, white blood cells, and platelets.
Please see the Full Prescribing Information.
ONCASPAR should not be given to patients who have had:
- Serious allergic reactions to ONCASPAR (pegaspargase) or any of its ingredients.
- Serious blood clots, serious inflammation of the pancreas (abdominal pain), or serious bleeding during previous L-asparaginase treatment.
- Serious impairment of liver function.
ONCASPAR may cause serious side effects including:
- Allergic reactions (Symptoms: hives and itching, a swollen tongue or throat, trouble breathing, dizziness, fainting).
- Inflammation of the pancreas (Symptoms: severe stomach pain, nausea, vomiting, fever, chills, diarrhea).
- Blood clots (Symptoms: severe headache, arm or leg swelling, shortness of breath, chest pain).
- Increased/excess sugar in the blood (Symptoms: Excessive thirst, increased amount of urine or urinary frequency).
- Unusual bleeding or bruising.
- Liver problems, including severe, life-threatening, or fatal veno-occlusive liver disease (VOD), and abnormalities in liver tests may develop during ONCASPAR treatment. Contact your doctor immediately if you experience jaundice, rapid weight gain, abdominal swelling, or right upper abdominal pain or tenderness.
Call or see your doctor right away if you develop any of these serious side effects or if symptoms get worse.
Before receiving ONCASPAR, tell your doctor about all your medical conditions, including if you:
- are pregnant or plan to become pregnant. ONCASPAR can harm your unborn baby. You should not become pregnant during treatment with ONCASPAR. Tell your doctor right away if you become pregnant or think you may be pregnant during treatment with ONCASPAR.
- Females who are able to become pregnant: You should use effective non-hormonal birth control (contraception) during treatment with ONCASPAR and for at least 3 months after the last dose.
- are breastfeeding or plan to breastfeed. It is not known if ONCASPAR passes into your breast milk. Do not breastfeed during treatment with ONCASPAR and for 1 month after your last dose.
How will I receive ONCASPAR?
- ONCASPAR will be given to you as an injection by your doctor as part of your chemotherapy treatment plan. It is important that you receive all of your treatment doses according to your doctor’s instructions.
- During treatment, you will be monitored, and if you experience side effects, your doctor may have to change your treatment.
The most common side effects of ONCASPAR include: low albumin blood level (hypoalbuminemia), elevated liver enzymes, fever with low white blood cell count, abnormal elevation of triglyceride levels in the blood (hypertriglyceridemia), a high level of blood sugar (hyperglycemia), increased bilirubin level, inflammation of the pancreas, abnormal clotting studies, embolic and thrombotic events, allergic reactions, sepsis, and infections.
This is not a complete list of side effects that may occur. Call your doctor for medical advice about any side effects especially if they do not go away.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Servier Pharmaceuticals LLC at 1-800-807-6124.
For additional information, please refer to the ONCASPAR Full Prescribing Information and discuss any questions with your doctor.
ONCASPAR is a registered trademark of Servier IP UK Ltd., a wholly-owned, indirect subsidiary of Les Laboratoires Servier. Servier and the Servier logo are trademarks of Les Laboratoires Servier.
INDICATIONS AND USAGE
Approved use for ONCASPAR
ONCASPAR is a prescription medicine that is given as part of a chemotherapy treatment plan
to treat children and adult patients who have acute lymphoblastic leukemia (ALL), especially
for those patients who are allergic to native forms of L-asparaginase. ALL is a type of cancer
in which the bone marrow makes too many abnormal white blood cells that may crowd out normal
red blood cells, white blood cells, and platelets.
Please see the Full Prescribing Information.
Support Bot
Online
Welcome to the ServierONE chatbot!
I’m here to help you find information and resources on the ServierONE website.
Before we get started, are you a patient or a healthcare provider?